Dear IEHP Providers,

According to the FDA recall guidance, Title 21 Code of Federal Regulations Part 7 (21 CFR part 7), recalled products must be promptly removed or corrected. In an effort to promote health and wellness of our members, please review your records and notify members who may have been impacted by these recalls and market withdrawals.

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Product Code</th>
<th>Lot # and Exp. Date</th>
<th>Classification</th>
<th>Recalling Firm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceftazidime 2 g for Injection and Dextrose for Injection 50 mL Duplex Container</td>
<td>NDC: 00264-3145-11</td>
<td>H8J812 Exp. 07/31/2020</td>
<td>Class I</td>
<td>B. Braun Medical Inc</td>
</tr>
<tr>
<td>Nizatidine 15 mg/mL (75 mg/5mL) Oral Solution</td>
<td>NDC: 60846-0301-15</td>
<td>06598004A Exp. 04/2020; 06599001A, 06599002A Exp. 12/2020</td>
<td>Class II</td>
<td>Amneal Pharmaceuticals of New York, LLC</td>
</tr>
<tr>
<td>Lactated Ringer’s Injection</td>
<td>NDC: 00409-7953-09</td>
<td>07-514-FW Exp 07/01/2021</td>
<td>MW</td>
<td>ICU Medical Inc</td>
</tr>
<tr>
<td>Finasteride Plus 1.25mg Capsules</td>
<td>NDC Not Provided</td>
<td>02-27-2020:04@11</td>
<td>MW</td>
<td>MasterPharm, LLC</td>
</tr>
<tr>
<td>Epinephrine Injection 0.3 mg (Auto-Injector) 0.3 mg/0.3 mL pre-filled syringe</td>
<td>NDC: 00093-5986-27</td>
<td>007F19AA Exp. 04/2021</td>
<td>Class II</td>
<td>Teva Pharmaceuticals USA</td>
</tr>
<tr>
<td>Infuvite Pediatric Pharmacy, kit in 1 carton (40 mL fill in a 50 mL) vial 1 and (10 mL) in vial 2</td>
<td>NDC: 54643-5647-00</td>
<td>JX907 Exp. 02/2021</td>
<td>Class II</td>
<td>Sandoz, Inc</td>
</tr>
<tr>
<td>Finasteride Plus 1.25 mg Capsule, 30, 90-count Bottle, Compounded Product Not for Resale</td>
<td>NDC Not Provided</td>
<td>02-27-2020:04@11, Exp. 08/25/2020</td>
<td>Class I</td>
<td>MasterPharm LLC</td>
</tr>
<tr>
<td>NP Thyroid 30 mg</td>
<td>NDC: 42192-0329-01</td>
<td>M329H18-1 Exp. 07/2020; M329M18-2 Exp. 11/2020; M329J18-1, M329J18-2, M329J18-3 Exp.08/2020; M329A19-1 Exp. 12/2020</td>
<td>MW</td>
<td>Acella Pharmaceuticals, LLC</td>
</tr>
</tbody>
</table>
### NP Thyroid 60 mg
- NDC: 42192-0330-01
- M330J18-2A, M330J18-3 Exp. 08/2020
- MW
- Acella Pharmaceuticals, LLC

### NP Thyroid 90 mg
- NDC: 42192-0331-01
- M331G18-1 Exp. 06/2020; M331J18-1, M331J18-2 Exp. 08/2020; M331M18-1, M331M18-2 Exp. 11/2020;
- MW
- Acella Pharmaceuticals, LLC

### Lactated Ringer’s Injection 1000 mL flexible container
- NDC: 00409-7953-09
- 07-514-FW Exp. 07/01/2021
- Class I
- ICU Medical Inc

### Aloprim (allopurinol sodium) 500 mg for Injection Single-Dose Vial
- NDC: 67457-0187-50
- N1700771 Exp. 10/2020; N1800127 Exp. 02/2021
- Class II
- Mylan Institutional LLC

### Metformin Hydrochloride Extended-Release 500 mg Tablets
- NDC: 60505-0260-01
- All lots with expiry
- MW
- Apotex Corp

---

I = Class I Recall, II = Class II Recall, MW = Market Withdrawal

Additional information can be found at:
1. FDA Recalls, Market Withdrawals, & Safety Alerts: [https://www.fda.gov/Safety/Recalls/default.htm](https://www.fda.gov/Safety/Recalls/default.htm)

If you have any questions or comments regarding this recall, please call IEHP Pharmaceutical Services Department at 909-890-2049, 8am – 5pm (PST), Monday through Friday.

Sincerely,

IEHP Pharmaceutical Services